We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
- Authors
Socinski, Mark A; Novello, Silvia; Brahmer, Julie R; Rosell, Rafael; Sanchez, Jose M; Belani, Chandra P; Govindan, Ramaswamy; Atkins, James N; Gillenwater, Heidi H; Pallares, Cinta; Tye, Lesley; Selaru, Paulina; Chao, Richard C; Scagliotti, Giorgio V
- Abstract
Aberrant vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) signaling have been shown to play a role in non-small-cell lung cancer (NSCLC) pathogenesis and are associated with decreased survival. We evaluated the clinical activity and tolerability of sunitinib malate (SU11248), an oral, multitargeted tyrosine kinase inhibitor that blocks the activity of receptors for VEGF and PDGF, as well as related tyrosine kinases in patients with previously treated, advanced NSCLC.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 4, p650
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.13.9303